Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Pfizer
Tizona Therapeutics, Inc
Novartis
AstraZeneca
Genentech, Inc.
DEKA Biosciences
Columbia University
Inhibrx Biosciences, Inc
Celldex Therapeutics
AO GENERIUM
Bristol-Myers Squibb
Quadriga Biosciences, Inc.
Imperial College London
Pfizer
Shanghai Junshi Bioscience Co., Ltd.
Celgene
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Celldex Therapeutics
Ohio State University Comprehensive Cancer Center
Santa Maria Biotherapeutics
Virginia Commonwealth University
Northwestern University
The Cleveland Clinic
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Indiana University
Yale University
University of Chicago
Altor BioScience
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cytheris SA
National Institutes of Health Clinical Center (CC)
ZymoGenetics